MAIA Biotechnology, Inc. (MAIA)
| Market Cap | 72.06M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -23.72M |
| Shares Out | 21.84M |
| EPS (ttm) | -1.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 416,351 |
| Open | 3.000 |
| Previous Close | 3.120 |
| Day's Range | 3.000 - 3.435 |
| 52-Week Range | 0.820 - 3.590 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2024 |
About MAIA
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. [Read more]
Financial Performance
Financial StatementsNews
MAIA Biotechnology to Present at the BIO International Convention 2024
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at the BIO International Convention 2024.
MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Abstract Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.
MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Adelina Louie in Private Placement.
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Stan Smith, Ph.D. in Private Placement.
MAIA Biotechnology Announces $1.00 Million Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.00 Million Private Placement.
MAIA Biotechnology to Present at Two Investor Conferences in April 2024
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Two Investor Conferences in April 2024.
MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchases by Directors Cristian Luput and Ramiro Guerrero.
MAIA Biotechnology Announces $1.33 Million Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.33 Million Private Placement.
MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Share Purchase by Director Stan Smith, PhD in a $2.9 Million Private Placement.
MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board.
MAIA Biotechnology to Participate in the 36th Annual ROTH Conference
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Participate in the 36th Annual ROTH Conference.
MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at American Association of Cancer Research Annual Meeting
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology and Nationwide Children's Hospital Announce Presentation of THIO's Potency in Pediatric Brain Tumors at AACR Annual Meeting.
MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Strong Efficacy of THIO as Third-Line Treatment for Non-Small Cell Lung Cancer Patients.
MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology CEO Details Immuno-Oncology Cancer Treatment Candidates and Development Pipeline in Letter to Shareholders.
MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies f...
MAIA Biotechnology Completes Enrollment in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
CHICAGO, IL, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies f...
MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication in Nature Communications on Positive Effects of THIO for Potential Treatment of Small Cell Lung Cancer.
MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds.
MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Provides Positive Phase 2 Clinical Updates for Lead Anticancer Agent and Outlines Targeted Milestones for 2024.
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024.
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer.
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering.
MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
CHICAGO, IL / ACCESSWIRE / November 17, 2023 / More than 300,000 people are diagnosed with brain cancer across the globe each year. Glioblastoma represents the majority of these cases in the U.S., wit...
MAIA Biotechnology Announces $4 Million Registered Direct Offering
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $4 Million Registered Direct Offering.
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
CHICAGO--(BUSINESS WIRE)--FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma.